Post-traumatic stress disorder (PTSD) is associated with an increased risk of developing systemic lupus erythematosus (SLE), with emerging evidence linking chronic psychological stress to immune ...

BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory ...

Although it did not meet the primary endpoint of dose-response relationship, when compared to placebo, enpatoran demonstrated improvements in measures of both systemic and cutaneous disease activity ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

The leading causes of readmission among patients who received THA included sepsis (14.6%), nonseptic infections (14.8%), cardiovascular events (11.2%), and pulmonary complications (8.4%). Common ...

Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the ...

The guideline recommendations advise universal use of hydroxychloroquine, minimizing steroids, and earlier introduction of ...

Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

In a new study, researchers identified eight disease activity domains for further development into the new Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE), a clinical trial ...

This study is being conducted to evaluate the safety, tolerability, and ability to manufacture Descartes-08, an investigational mRNA CAR-T cell therapy, in people living with moderate to severe ...